MYST acetyltransferases are a targetable therapeutic vulnerability in SETBP1-mutant leukemia
SETBP1 mutations are markers of high-risk myeloid malignancies, but we lack any targeted therapies to improve outcomes. In this study, we identify MYST acetyltransferases as key drivers of mutant SETBP1-driven transcription. MYST inhibitors are highly effective against SETBP1-mutant leukemia and represent a promising avenue for clinical translation.
Institutions
- Pacific Northwest National Laboratory (US)
- Oregon Health & Science University (US)
- Moffitt Cancer Center (US)
- OHSU Knight Cancer Institute
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-01-08
- DOI
- https://doi.org/10.64898/2026.01.08.697228
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00